Evolva and Abunda widen collaboration in the Field of Human Nutrition
Evolva Holding SA announced that it has signed an agreement with San Francisco, California-based Abunda Nutrition, Inc. to extend and expand their research collaboration. In this collaboration Evolva’s technology platform is applied to create new and optimised production methods for certain high-value food ingredients.
The research will run for a minimum of two years and primarily be located at Evolva’s Denmark and India sites. Around ten scientists from Evolva will be engaged on the program. Abunda will provide the majority of the funding and Evolva will be entitled to a double-digit share of the total commercial returns from the project. Further details regarding the agreement remain undisclosed. The new agreement does not change Evolva’s revenue forecast for 2010.
“We are very pleased that Abunda has decided to extend and expand our existing relationship", said Evolva CEO and Managing Director Neil Goldsmith. "In addition to the vanillin collaboration that we recently announced, this deal demonstrates the versatility of our synthetic biology platform and we are excited by the commercial potential of the products within the collaboration. We are delivering on our promise to increase our partnership portfolio in 2010.”
"We are proud to be working with Evolva and are delighted to expand our discovery and development collaboration with Evolva - ahead of schedule", said Abunda President and CEO Simon Waddington. "We believe this collaboration speaks volumes about the quality of our science and technology, the value proposition of our next-generation nutritional ingredients and production methods, and the role that we are playing in this field to bring innovative new products to the market to improve health and wellness."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Sartorius acquires French provider of innovative upstream technologies for cell and gene therapies - Agreed purchase price of approximately 2.4 billion euros
Category:Fertility_medicine
Effects of chemical mixtures: Neurotoxic effects add up - Study demonstrates for the first time the toxicological relevance of chemical mixtures as they occur in humans
Innovative approach to treat autism spectrum disorders - University of Basel spin-off Translation-X receives Venture Kick funding
Shifting meetings, conventions online curbs climate change - The annual carbon footprint for the global event and convention industry is on par with the yearly greenhouse gas emissions of the entire U.S.
Photocure announces positive results of Phase 2B study evaluating Visonac in acne
Dental_porcelain
Rockeby awarded bird flu tests tender from Middle East
Rentschler focuses on biotechnology
How cancer genes become independent - Study sheds light on the mysterious evolution of DNA rings
